The promise of CRISPR editing will not be realized without meaningful innovation in scalability, efficiency and access.
Gene editing using the MAD7™nuclease has been demonstrated in both E. coli and yeast organisms, and now in mammalian cells.
Here we describe the MAD7 nuclease, a system that targets TTTN PAMs and shows both cutting and editing activity in E. coli and S. cerevisiae.
To address the need for an expanded range of nucleic acid-directed endonucleases, Inscripta is developing new classes of RNA-guided…
Poster presentation at 2019 GP‑W & SC2.0 Meeting. The Onyx platform developed by Inscripta Inc., dramatically increases the scale of Digital Genome Engineering and simplifies the complex editing workflow for biologists.
